45 results about "Pharmaceutical Dose Form" patented technology

There is provided a pharmaceutical dosage form that is suitable for peroral administration to the gastrointestinal tract, which dosage form comprises a pharmaceutical composition in the form of a particulate mixture comprising solid particles of N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide (C21), or a pharmaceutically-acceptable salt thereof, admixed with a blend of carrier particles with weight- and / or a volume-based mean diameter, and / or a structural / particle density, that is / are similar to the weight- and / or volume-based mean diameter, and / or the structural / particle density, of the solid particles of C21, and a glidant, which composition is contained within a capsule that is suitable for such peroral administration. Preferred carrier particles have a weight- and / or a volume-based mean diameter that is less than about 100 μm. Preferred carrier particle materials include mannitol. Preferred glidants comprise colloidal silica. Such dosage forms find utility in the treatment of lung diseases, such as idiopathic pulmonary fibrosis, sarcoidosis and respiratory virus-induced tissue damage.

The invention belongs to the technical field of medicine dosage forms, and particularly relates to a conjugated estrogen-progestational hormone double-layer tablet and a preparation method thereof. The preparation method comprises the following steps: performing powder mixing on conjugated estrogen and a first medicine auxiliary material to obtain conjugated estrogen powder; carrying out wet granulation on progestational hormone and a second medicine auxiliary material to obtain progestational hormone granules; and tabletting the conjugated estrogen powder and the progestational hormone particles by using a double-layer tablet press to obtain the conjugated estrogen-progestational hormone double-layer tablet. The conjugated estrogen-progestational hormone double-layer tablet prepared by the invention can simultaneously meet the slow release of conjugated estrogen and the quick release of progestational hormone, so that the medicine taking frequency is reduced, and the compliance of a patient is improved; and meanwhile, the stability of a drug bound with estrogen and the bioavailability of progestational hormone are improved.

The present disclosure relates generally to pharmaceutical dosage forms comprising azacitidine and chidaridine.

The invention belongs to the technical field of biological medicines, and particularly relates to application of an ITGA6 inhibitor in preparation of a medicine for treating uveal melanoma. By integrating bioinformatics analysis of databases of TCGA, GTEx, CPTAC and the like, the invention systematically reveals that the ITGA6 has high specific expression in uveal melanoma and is significantly related to poor prognosis of a patient for the first time. In-vitro experiments prove that by knocking down ITGA6, proliferation, migration, invasion and colony forming ability of UVM cells can be effectively inhibited. According to the invention, small molecular compounds such as 4.5-diphenyl-1H-imidazole, MS-275, W-13 and the like and siRNA (small interfering Ribonucleic Acid) targeting ITGA6 are screened out to be used as effective inhibitors, and specific drug dosage forms such as intraocular injection and the like are provided. In addition, the ITGA6 inhibitor can be used in combination with a PD-1 / PD-L1 inhibitor, a CTLA-4 inhibitor or a chemotherapeutic drug to generate a synergistic anti-tumor effect. Mechanism research shows that ITGA6 promotes UVM progress by regulating a signal channel and a tumor immune microenvironment. The invention provides a new targeted treatment strategy for uveal melanoma, and has important clinical application value.

The present disclosure provides a method for the treatment of Parkinson's disease comprising simultaneously or sequentially administering to a patient in need of treatment of Parkinson's disease a dosage form comprising(i) levodopa in an amount ranging from 50 mg to 300 mg,(ii) carbidopa in an amount ranging from 25 mg to 150 mg or a therapeutically equivalent amount of another aromatic amino acid decarboxylase inhibitor, and(iii) entacapone in an amount ranging from 50 mg to 300 mg, wherein the proportion of entacapone to carbidopa in said dosage form ranges from 0.3:1.0 to 3.2:1.0 by weight, a moderately potent COMT inhibitor in an amount ranging from 25 mg to 200 mg, wherein the proportion of said COMT inhibitor to carbidopa in said dosage form ranges from 0.16:1.0 to 3.08:1.0 by weight, or a highly potent COMT inhibitor in an amount ranging from 1 mg to 100 mg, wherein the proportion of said COMT inhibitor to carbidopa in said dosage form ranges from 0.006:1.0 to 1.54:1.0 by weight. Pharmaceutical dosage form used in said method are also disclosed.

The present disclosure generally relates to the use of polyvinyl alcohol (PVA) in additive manufacturing technologies and techniques. More specifically, the present disclosure relates to the use of PVA in a selective laser sintering (SLS) method to additively manufacture an object, in particular a pharmaceutical dosage form.

The invention relates to pharmaceutical compositions comprising: (a) at least one angiotensin receptor blocker or a pharmaceutically acceptable salt thereof, and (b) at least one chemokine receptor pathway inhibitor or a pharmaceutically acceptable salt thereof. The invention also relates to pharmaceutical compositions comprising: (a) at least one angiotensin receptor blocker or a pharmaceutically acceptable salt thereof; and (b) at least one chemokine receptor pathway inhibitor or a pharmaceutically acceptable salt thereof that inhibits a component of the chemokine receptor pathway other than the chemokine receptor. Sustained-release oral pharmaceutical compositions comprising the pharmaceutical composition are described, as well as sustained-release injectable pharmaceutical compositions comprising the pharmaceutical composition.The invention further relates to tablets, capsules, injectable suspensions, and compositions for pulmonary or nasal administration comprising the pharmaceutical composition. Also described are: methods for evaluating the efficacy of the pharmaceutical composition; methods for evaluating the inhibitory or partial inhibitory activity of the pharmaceutical composition; methods for treating, alleviating, or preventing a condition or disease comprising administering a therapeutically effective amount of the pharmaceutical composition to a subject; and the use of the pharmaceutical composition for manufacturing a pharmaceutical dosage form for the treatment of a disease.

The invention concerns an orally administrable pharmaceutical dosage form configured for targeted delivery to the distal part of the gastrointestinal tract of a human subject, wherein the pharmaceutical dosage form comprises lanthanum or a pharmaceutically acceptable salt or oxide thereof. The invention further relates to the pharmaceutical dosage form for use in the treatment of hyperoxaluria in a human subject, optionally wherein the hyperoxaluria is primary hyperoxaluria or secondary hyperoxaluria; and / or for use in the treatment of one or more of nephrolithiasis, nephrocalcinosis, or oxalosis in a human subject.

The invention relates to a pharmaceutical dosage form for oral administration comprising (i) an intragranular phase, which comprises Sertraline or a physiologically acceptable salt thereof; one or more intragranular fillers (preferably selected from one or more sugar alcohols or sugars; preferably mannitol or lactose, more preferably mannitol); one or more intragranular antioxidants (preferably selected from butylated hydroxytoluene (BHT), butylated hydroxy anisole (BHA), tocopherol or derivatives thereof, ascorbic acid or derivatives thereof, sodium metabisulphite, propyl gallate, sodium thiosulphate, or any combination thereof, more preferably ascorbic acid); (ii) an extragranular phase, which comprises one or more extragranular fillers (preferably mannitol, microcrystalline cellulose, lactose, or any combination thereof); and (iii) optionally, a film coating. The invention further relates to a process for manufacture by wet granulation, wherein the antioxidant is preferably dissolved in the granulation liquid.

The present invention is to provide an amorphous solid dispersion comprising elacestrant dihydrochloride of formula (I), in combination with one or more pharmaceutically acceptable excipients such as a stabilizing agent including a polymer and / or an alkalizing agent. Additionally, the invention provides a process for the preparation of such amorphous solid dispersions and an amorphous form of elacestrant dihydrochloride. The resulting amorphous form or amorphous solid dispersions are advantageous for the formulation of pharmaceutical dosage forms and compositions, enhancing the bioavailability and stability of elacestrant dihydrochloride.

The present invention relates to a water-soluble film containing mometasone furoate, adjusted to a pH in the range of 3.5 to 5.0. Adjusting the pH improves the stability of the active ingredient without significantly affecting the mechanical properties of the film. The present invention further relates to methods for producing such films, pharmaceutical dosage forms containing such films in a capsule, and methods for producing such pharmaceutical dosage forms. The pharmaceutical dosage form can be used, in particular, for the treatment of eosinophilic esophagitis.

A tamper resistant drug dosage is described. The drug dosage form includes a matrix polymer, a scaffold polymer, and a therapeutic agent, and the porosity of the drug dosage form is less than 10%. Methods for making and using the tamper resistant drug dosage forms are described.

Disclosed herein are materials, articles of manufacture, and methods for reducing, mitigating, or precluding formation of and / or amount of a nitrosating agent and / or an N-nitroso compound, including an N-nitrosamine, from a packaging containing an active agent and a pharmaceutical dosage form in an enclosure, wherein the active agent is effective to reduce mitigate or preclude the formation and / or amount of a nitrosating agent and / or N-nitroso compound in the enclosure and / or in the pharmaceutical dosage form. Provided are drug delivery systems comprising a blister pack configured to house multiple pharmaceutical dosage forms, the blister pack comprising an active ingredient that is effective to reduce, mitigate or preclude the formation and / or amount of a nitrosating agent and / or N-nitroso compound in an enclosure of the blister pack and / or in the pharmaceutical dosage form.

The invention discloses hollow adhesive microspheres loaded with rebamipide as well as a preparation method and application of the hollow adhesive microspheres, and belongs to the technical field of improvement of pharmaceutical dosage forms. The preparation method of the rebamipide-loaded hollow adhesive microspheres comprises the following steps: mixing ethyl cellulose, an acrylic resin material and rebamipide in a mixed solvent prepared from a chloralkane solvent and an alcohol solvent to obtain an oil phase solution; mixing polyvinyl alcohol and an oil-in-water surfactant in water to obtain a water phase solution; adding the oil phase solution into the water phase solution, mixing and volatilizing under a stirring condition, and forming a porous cavity structure with a fiber interpenetrating network through liquid-liquid phase separation in a stirring process, so as to obtain the rebamipide hollow microspheres; and carrying out adhesion coating on the rebamipide hollow microspheres to obtain the rebamipide-loaded hollow adhesion microspheres. The rebamipide-loaded hollow adhesive microspheres prepared by the invention can be detained in the stomach for a long time to realize controllable release, so that the bioavailability and the treatment effect of rebamipide are improved.

The present application relates to a pharmaceutical dosage form and a method for preparing the same, such as a pharmaceutical dosage form prepared by a three-dimensional printing method. A pharmaceutical dosage form loaded with a liquid or semi-solid material and a pharmaceutical dosage form loaded with a solid material are both provided.

The present invention relates to a pH responsive polymer composition for the enteric coating of hard shell capsules, which composition is suitable for the delivery of pharmaceutical dosage forms, in particular microbiota, to the ileum and colon. The pH responsive polymer composition comprises at least one anionic poly (meth) acrylate copolymer, at least one glidant, at least one plasticizer, and 1 to < 6% of at least one nonionic emulsifier based on the total weight of the pH responsive polymer composition.

A novel medical use of ingenol HEP14, a dosage form of an HEP14-based drug, and a preparation method for the dosage form. The dosage form of the HEP14-based drug is an HEP14 / PLGA microsphere sustained-release dosage form formed by encapsulating the HEP14-based drug with a polylactic acid-glycolic acid copolymer, and has the functions of high HEP14 drug loading rate, high encapsulation rate, and long-acting HEP14 sustained-release. It has been found for the first time that HEP14 can promote production and autophagy of mitochondria in cells and enhance the function of mitochondria in cells, promote the secretion of antioxidant enzymes and remove reactive oxygen species, promote the growth and viability of ovarian follicle granulosa cells and restore the growth and viability of aging granules, promote the secretion of angiogenic factors, reduce the fibrosis of ovarian tissues, promote the angiogenesis of ovarian tissues, and promote the regeneration of aged ovarian follicles and ovarian endocrine functions, and thus has a good effect of treating and / or preventing related diseases caused by mitochondrial dysfunction, especially the effect of treating age-related ovarian decline.

The utility model discloses a kind of be applied to the comminuting device of crude drug, including base, control mechanism is installed in the upper portion of base, the control mechanism is connected with comminuting mechanism;Motor drive screw feeder feeds and comminutes to the comminuting mechanism.The control mechanism includes the control box being installed in the upper portion of base, switch is arranged on the control box, for starting or closing the comminuting mechanism;It also includes external frequency converter and control system, the frequency converter and the control system are connected with the comminuting mechanism and the control box by communication module or cable.The product granularity of device after grinding is finer, smallest can make material evenly reach 200 microns, can improve drug dissolution rate and bioavailability, enhance preparation uniformity and stability, expand drug dosage form and application range, can satisfy the demand of different customer groups, increase product added value and its sales volume.

Pharmaceutical oral solid dosage forms including liothyronine and levothyroxine salts and methods of making and using the pharmaceutical oral solid dosage forms are disclosed.

The disclosure is directed to improved methods of treating minor pain in humans using a pharmaceutical dosage form comprising acetaminophen in admixture with naproxen.

Described are continuous manufacturing methods using 3D printing or any similar additive manufacturing technology to produce pharmaceutical dosage forms or pharmaceutical delivery devices. Manufacturing methods using hot-melt extrusion to fabricate filaments for fused deposition modeling (FDM) based 3D printing are disclosed. Methods using FDM based 3D printing to fabricate printed products suitable for pharmaceutical delivery purposes are disclosed. The printed products may have various shapes and configurations.

The present invention particularly relates to (i) a combination of a CBP / p300 bromodomain inhibitor and a KRAS inhibitor for treating a patient with cancer, wherein the cancer exhibits carcinogenic alterations in KRAS; (ii) a kit comprising (a) a pharmaceutical formulation containing a CBP / p300 bromodomain inhibitor and (b) a pharmaceutical formulation containing a KRAS inhibitor; and (iii) a pharmaceutical formulation comprising a CBP / p300 bromodomain inhibitor and a KRAS inhibitor.

The present invention relates to a process for the production of pharmaceutical dosage forms by powder bed melt selective laser three-dimensional printing, in particular selective laser sintering three-dimensional printing (SLS), and to pharmaceutical dosage forms produced by this process.

The present invention relates to a water-soluble film having a mometasone furoate content adjusted to a pH in the range of 3.5 to 5.0. The correspondingly adjusted pH increases the stability of the active ingredient without substantially impairing the mechanical properties of the film. The present invention further relates to methods for producing such films, pharmaceutical dosage forms containing films of the above type in a capsule, and methods for producing such pharmaceutical dosage forms. The pharmaceutical dosage form can especially be used for treating eosinophilic esophagitis.

This disclosure relates to dosage forms comprising: 1) about 100-110 mg, about 104-106 mg, or about 105 mg of bupropion hydrochloride, or a molar equivalent amount of the free base form or another salt form of dextromethorphan; and 2) about 25-35 mg, about 29-31 mg, about 30 mg, about 40-50 mg, about 44-46 mg, or about 45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of the free base form or another salt form of dextromethorphan. In some embodiments, a dosage form as described herein is free of a Compound I and Compound II. In some embodiments, a dosage form may contain 0.5 ng to 750 ng of Compound I, 0.5 ng to 750 ng of Compound II, or a combination thereof. These dosage forms may be used to treat various neurological and psychiatric conditions, including major depressive disorder, agitation associated with Alzheimer's disease, and nicotine addiction.

Additive manufacturing systems for producing pharmaceutical products and methods for operating these systems are disclosed. In some embodiments, the system allows for additive manufacturing of pharmaceutical dosage forms in a flexible, scalable, modular, and reconfigurable manner while maintaining high throughput over time.

The present invention relates to a pharmaceutical dosage form comprising a drug with rapid absorption in the intestinal tract, which drug is absorbed in the distal intestinal tract, including the colon, and for which a pulsed release is necessary to avoid the potential toxicity of sustained absorption of the drug, and a method of preparing the pharmaceutical composition. In particular, the present invention relates to a dosage form comprising a formulation in the form of small coated units to deliver an active ingredient after oral administration for a predetermined period of time. In a preferred embodiment, the drug is an iron chelating agent deferiprone.

The present disclosure relates generally to pharmaceutical dosage forms comprising azacitidine and cedazuridine.

A pharmaceutical dosage form comprises a capsule shell and a fill composition, wherein the fill composition comprises an emulsion of (a) simethicone, (b) loperamide or a pharmaceutically acceptable salt thereof, and (c) at least two surfactants, wherein the emulsion has a hydrophilic lipophilic balance ranging from about 8 to about 12. Also described are methods of making the pharmaceutical dosage forms and methods for treating humans suffering from gastrointestinal distress.